#cosentyx — Public Fediverse posts

https://www.europesays.com/ch/81819/ Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients #Cosentyx #NewEnglandJournalOfMedicine #Novartis #pediatric patients #PolymyalgiaRheumatica #RheumaticDisease #TreatmentArms

https://www.europesays.com/ch/80004/ Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients #Cosentyx #NewEnglandJournalOfMedicine #Novartis #pediatric patients #PolymyalgiaRheumatica #RheumaticDisease #TreatmentArms

https://www.europesays.com/ch/78688/ Novartis Presents 31 Immunology Abstracts at EULAR 2026 #AutoimmuneDiseases #CARTTherapy #Cosentyx #EULAR2026 #ianalumab #Immunology #Novartis #RapCel #secukinumab

https://www.europesays.com/ch/78462/ Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica #Cosentyx #Novartis #NovartisAG #RemissionRates

https://www.europesays.com/ch/77574/ Cosentyx PMR Data Puts Novartis Pipeline And Earnings Story In Focus #Cosentyx #indication #InvestmentDecisions #Novartis #PMRResults #PolymyalgiaRheumatica #RegulatoryFilings #TreatmentOptions

https://www.europesays.com/ch/77280/ Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients #Cosentyx #NewEnglandJournalOfMedicine #Novartis #pediatric patients #PolymyalgiaRheumatica #RheumaticDisease #TreatmentArms

https://www.europesays.com/ch/77033/ Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients #as #Cosentyx #data #England #in #journal #many #medicine #new #Novartis #of #patients #placebo #PMR #remission #showed #sustained #twice #Vs

https://www.europesays.com/ch/76693/ Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 #AAD #ChronicDiseases #ChronicSpontaneousUrticaria #Cosentyx #DataIntegrity #DataPrivacy #EfficacyData #HidradenitisSuppurativa #Novartis #OralPresentation

https://www.europesays.com/ch/36921/ Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 #AAD #ChronicDiseases #ChronicSpontaneousUrticaria #Cosentyx #DataIntegrity #DataPrivacy #EfficacyData #HidradenitisSuppurativa #Novartis #OralPresentation

https://www.europesays.com/ch/32987/ Novartis wins FDA approval for Cosentyx to treat paediatric HS patients #Cosentyx #Cosentyx dosing #FoodAndDrugAdministration #Novartis #paediatric patients #TreatmentOption

https://www.europesays.com/ch/32969/ Novartis wins FDA approval for Cosentyx to treat paediatric HS patients #Cosentyx #FoodAndDrugAdministration #Novartis #paediatric patients #TreatmentOption

https://www.europesays.com/ch/32580/ Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa #Cosentyx #FDA #HidradenitisSuppurativa #Novartis #pediatric patients #PsoriaticArthritis #TreatmentOption #TreatmentOptions

https://www.europesays.com/ch/31642/ Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa #Cosentyx #FDA #HidradenitisSuppurativa #Novartis #pediatric patients #PsoriaticArthritis #TreatmentOption #TreatmentOptions